Biochemistry Quiz: Metabolic Disorders And Pathway Defects

What this quiz covers

This quiz focuses on Metabolic Disorders And Pathway Defects, giving you a quick way to practice the rules, question types, and explanations that matter most for Biochemistry.

How to use this quiz

Try each quiz question before looking at the correct answer. Use the explanations to review missed ideas, then come back to similar questions until the pattern feels familiar.

Question 1

1. The byproduct phenylpyruvate acts as a potent neurotoxin by directly uncoupling oxidative phosphorylation in neurons.
2. High levels of phenylalanine competitively inhibit the transport of other large neutral amino acids into the brain. (correct answer)
3. The lack of dietary phenylalanine prevents the synthesis of essential myelin proteins required for nerve insulation.
4. Accumulated phenylalanine is mistakenly incorporated into proteins in place of tyrosine, leading to widespread protein misfolding.

Explanation: When you encounter questions about metabolic disorders like PKU, focus on understanding the specific enzyme deficiency and its downstream consequences rather than getting distracted by complex-sounding mechanisms. PKU results from deficiency in phenylalanine hydroxylase, which normally converts phenylalanine to tyrosine. This leads to massive accumulation of phenylalanine in blood and tissues. The primary mechanism of neurological damage involves the blood-brain barrier's amino acid transport system. Large neutral amino acids (phenylalanine, tyrosine, tryptophan, and others) compete for the same transporter to enter the brain. When phenylalanine levels are extremely elevated, it outcompetes other essential amino acids, preventing them from reaching brain tissue where they're needed for neurotransmitter synthesis and normal brain development. Choice A incorrectly suggests phenylpyruvate directly uncouples oxidative phosphorylation. While phenylpyruvate does accumulate as a byproduct, this isn't the primary mechanism of brain damage. Choice C gets the relationship backward—PKU patients need to restrict, not increase, phenylalanine intake, and the problem isn't lack of dietary phenylalanine. Choice D describes protein misincorporation, but phenylalanine and tyrosine are distinct amino acids with different codons, so this substitution doesn't occur during protein synthesis. The correct answer is B because competitive inhibition of amino acid transport explains why PKU patients develop intellectual disability despite having adequate nutrition otherwise—their brains are essentially starved of crucial amino acids needed for normal development. Remember: metabolic disorder questions often test transport and competition mechanisms, not just the primary enzyme deficiency.

Question 2

1. accelerated proteolysis in muscle to supply amino acid substrates, such as alanine, for hepatic gluconeogenesis. (correct answer)
2. the direct conversion of muscle protein into ketone bodies within myocytes to be used as an alternative fuel source.
3. toxic effects of hyperglycemia that cause non-enzymatic degradation of actin and myosin contractile filaments.
4. a global shutdown of cellular respiration in muscle cells due to the inability to import sufficient glucose.

Explanation: The correct answer is A. In the insulin-deficient state of T1D, the body enters a catabolic, fasted-like state. The liver is performing high rates of gluconeogenesis to produce glucose that the body cannot effectively use. A major source of carbon skeletons for this process is amino acids derived from the breakdown (proteolysis) of muscle protein. Alanine, in particular, is a key gluconeogenic precursor transported from muscle to the liver (the glucose-alanine cycle). This leads to a negative nitrogen balance, muscle wasting, and weight loss. B is incorrect because ketone bodies are synthesized from fatty acids, and this process occurs in the liver, not muscle. C is incorrect because while glycation of proteins occurs, it is not the primary mechanism of the rapid muscle wasting seen in acute T1D. D is incorrect because muscle cells can switch to using fatty acids as their primary fuel, so respiration does not shut down.

Question 3

1. Suppression of carnitine palmitoyltransferase I (CPT1), leading to potent inhibition of ketogenesis.
2. Marked stimulation of fatty acid synthesis and subsequent VLDL packaging and export.
3. Persistent phosphorylation and activation of glycogen phosphorylase and inactivation of glycogen synthase. (correct answer)
4. Increased transcription of glucokinase to trap any incoming glucose within the hepatocyte.

Explanation: When you encounter questions about Type 1 diabetes and glucagon signaling, focus on understanding how insulin normally counterbalances glucagon's effects. In healthy individuals, insulin opposes glucagon's actions, but in insulin-deficient states, glucagon's metabolic effects become dominant and persistent. Glucagon's primary hepatic action involves activating protein kinase A (PKA) through the cAMP pathway. PKA then phosphorylates key regulatory enzymes in glycogen metabolism. Specifically, it phosphorylates and activates glycogen phosphorylase (promoting glycogen breakdown) while simultaneously phosphorylating and inactivating glycogen synthase (preventing glycogen synthesis). Without insulin to counteract this signaling, these enzymes remain in their glucagon-favored states, leading to persistent glycogenolysis. This explains why answer C is correct. Answer A is backwards - glucagon actually relieves CPT1 inhibition by reducing malonyl-CoA levels, thereby promoting ketogenesis, not suppressing it. Answer B contradicts glucagon's metabolic role; glucagon inhibits fatty acid synthesis and promotes fatty acid oxidation instead. The hormone shifts the liver toward catabolic rather than anabolic lipid metabolism. Answer D misrepresents glucagon's glucose-handling strategy - glucagon actually decreases glucokinase expression since its goal is to release glucose from the liver, not trap it within hepatocytes. Remember this pattern: glucagon promotes breakdown pathways (glycogenolysis, gluconeogenesis, fatty acid oxidation) while inhibiting synthesis pathways (glycogenesis, lipogenesis). In Type 1 diabetes, these effects become unopposed and excessive, leading to hyperglycemia and ketosis.

Question 4

1. Decreased glucose uptake by insulin-dependent tissues and uncontrolled hepatic glucose production. (correct answer)
2. Increased glucose uptake by the liver to produce glycogen and decreased glucose uptake by the brain.
3. A complete failure of glycolysis in all tissues, causing glucose to accumulate in the extracellular space.
4. Massive conversion of dietary carbohydrates directly into fatty acids, which inhibits glucose catabolism.

Explanation: The correct answer is A. The hyperglycemia of T1D has two main causes. First, the lack of insulin prevents the translocation of GLUT4 transporters in muscle and adipose tissue, severely impairing their ability to take up glucose from the blood. Second, the absence of insulin's suppressive signal on the liver, coupled with the unopposed action of glucagon, leads to continuous, uncontrolled gluconeogenesis and glycogenolysis, actively releasing glucose into the blood. This combination of decreased clearance and increased production causes profound hyperglycemia. B is incorrect because glucose uptake by the brain (via GLUT1/GLUT3) is largely insulin-independent, and the liver is producing, not storing, glucose. C is incorrect because glycolysis does not fail completely; tissues like the brain and red blood cells continue to use glucose. D is incorrect because fatty acid synthesis is an insulin-stimulated process and is profoundly inhibited in T1D.

Question 5

1. the enzymatic pathway for converting the essential amino acid phenylalanine to tyrosine is non-functional. (correct answer)
2. excess phenylalanine competitively inhibits the transport of dietary tyrosine across the intestinal wall, causing a deficiency.
3. tyrosine is rapidly catabolized into phenylpyruvate and other keto acids to compensate for high phenylalanine levels.
4. the synthesis of tyrosine from its precursor, glucose, is allosterically inhibited by high concentrations of phenylalanine.

Explanation: The correct answer is A. Phenylketonuria (PKU) is caused by a deficiency in the enzyme phenylalanine hydroxylase, which catalyzes the conversion of phenylalanine to tyrosine. Since the body cannot synthesize phenylalanine (it is an essential amino acid obtained from the diet), it relies on this conversion to produce tyrosine. When this enzyme is deficient, tyrosine cannot be synthesized from phenylalanine, making it essential to obtain it directly from the diet. B is incorrect because while high phenylalanine can interfere with transport of other large neutral amino acids, the primary reason tyrosine becomes essential is the lack of its synthesis. C is incorrect because tyrosine is not catabolized into phenylpyruvate; phenylalanine is. Tyrosine catabolism is not accelerated. D is incorrect because humans cannot synthesize tyrosine from glucose; it is synthesized from phenylalanine.

Question 6

1. Liver-specific glucokinase deficiency impairs glucose sensing and glycogen metabolism regulation
2. Hepatic glycogen synthase deficiency prevents glycogen storage in liver while muscle glycogen synthesis remains intact
3. Tissue-specific expression of glucose-6-phosphatase isoforms creates differential sensitivity to the enzymatic defect
4. Glucose-6-phosphatase deficiency prevents glucose release from liver glycogen but allows muscle glycogen to fuel local metabolism (correct answer)

Explanation: When you encounter glycogen storage diseases, focus on understanding which tissues are affected and why. The key is recognizing that different tissues use glycogen for different purposes and have different metabolic needs. Von Gierke disease results from glucose-6-phosphatase deficiency, which is crucial for the final step of gluconeogenesis and glycogenolysis. This enzyme converts glucose-6-phosphate to free glucose, allowing glucose to exit cells and enter the bloodstream. The liver's primary role is to maintain blood glucose levels during fasting by releasing glucose from glycogen breakdown. Without glucose-6-phosphatase, the liver cannot release glucose despite having normal glycogen stores and normal phosphorylase activity to break down glycogen to glucose-6-phosphate. This explains the hepatomegaly (enlarged liver full of glycogen) and fasting hypoglycemia (inability to release glucose). Muscle tissue, however, uses glucose-6-phosphate directly for its own energy needs through glycolysis. Muscle doesn't need to release free glucose into circulation, so the glucose-6-phosphatase deficiency doesn't impair muscle function. This is why muscle glycogen phosphorylase activity remains normal and muscle symptoms are minimal. Option A incorrectly identifies glucokinase as the problem. Option B suggests glycogen synthase deficiency, but patients actually have excess glycogen storage, not deficiency. Option C mentions isoforms, but the issue isn't differential sensitivity—it's the functional requirement difference between tissues. Remember: in glycogen storage diseases, always consider what each tissue needs to do with glucose and which enzymes are required for those specific functions.

Question 7

1. Respiratory alkalosis due to the over-excretion of acidic ketone bodies produced by fatty acid oxidation.
2. Lactic acidosis because the Cori cycle is blocked, but the TCA cycle continues to function normally.
3. Hyperglycemia resulting from the shunting of glycolytic intermediates into glycogen synthesis.
4. Severe hypoglycemia due to an inability to synthesize glucose from non-carbohydrate precursors. (correct answer)

Explanation: When you encounter enzyme deficiency questions, focus on the specific metabolic pathway that's disrupted and trace the downstream consequences. Fructose-1,6-bisphosphatase is a key regulatory enzyme in gluconeogenesis, catalyzing the conversion of fructose-1,6-bisphosphate to fructose-6-phosphate. This is one of the irreversible steps that allows the body to synthesize glucose from non-carbohydrate precursors like lactate, amino acids, and glycerol. During fasting states, when glycogen stores become depleted, gluconeogenesis becomes essential for maintaining blood glucose levels, especially for glucose-dependent tissues like the brain and red blood cells. Without functional fructose-1,6-bisphosphatase, the gluconeogenic pathway is blocked, preventing glucose synthesis from these alternative sources. During prolonged fasting, this leads to severe hypoglycemia as the body cannot compensate for falling blood glucose levels, making answer D correct. Answer A is incorrect because ketone body production actually helps prevent acidosis during normal fasting - they're not "over-excreted" and don't cause respiratory alkalosis. Answer B misunderstands the Cori cycle; while lactate recycling to glucose would be impaired, this doesn't specifically cause lactic acidosis through continued TCA cycle function. Answer C contradicts the actual consequence - without gluconeogenesis, glycolytic intermediates cannot be effectively converted to glucose, and glycogen synthesis requires glucose as a substrate. Remember: enzyme deficiencies in gluconeogenesis always think "fasting hypoglycemia." The body's backup glucose production system fails when dietary glucose and glycogen stores are insufficient.

Question 8

1. hemoglobin is glycated by fructose-derived metabolites, and its level reflects the patient's long-term sugar and fructose intake.
2. an enzyme, hemoglobin glycase, is upregulated by insulin and its activity reflects the average insulin signaling over several months.
3. the binding of glucose to hemoglobin permanently increases its oxygen affinity, providing a measurable index of chronic hyperglycemia.
4. the non-enzymatic glycation of hemoglobin is proportional to the average blood glucose concentration over the lifespan of an erythrocyte. (correct answer)

Explanation: When you encounter questions about HbA1c, focus on the fundamental biochemistry: non-enzymatic glycation and red blood cell lifespan. HbA1c reflects chronic glucose exposure because glucose spontaneously reacts with amino groups on hemoglobin through a non-enzymatic process called glycation. This reaction occurs continuously throughout the 120-day lifespan of red blood cells, and the amount of glycated hemoglobin formed is directly proportional to the average glucose concentration the cells encounter. Option D correctly captures this mechanism. The key insight is that this glycation is irreversible and accumulates over time, making HbA1c a reliable indicator of average blood glucose over 2-3 months (the typical red blood cell lifespan). Option A is incorrect because HbA1c primarily reflects glucose, not fructose metabolism. While fructose can contribute to glycation, glucose is the dominant sugar involved in HbA1c formation. Option B incorrectly describes an enzymatic process. There's no such enzyme as "hemoglobin glycase" involved in HbA1c formation. The glycation is non-enzymatic and occurs spontaneously when glucose concentrations are elevated. Option C misrepresents the functional consequence. While glycation does slightly alter hemoglobin's oxygen affinity, this isn't the basis for its clinical utility. The measurement relies on detecting the glycated hemoglobin itself, not changes in oxygen binding. Remember: HbA1c questions test your understanding of non-enzymatic glycation as a time-integrated measure of glucose exposure. The "non-enzymatic" aspect and the connection to red blood cell lifespan are crucial concepts that frequently appear on biochemistry exams.

Question 9

1. insufficient oxaloacetate in hepatocytes to accommodate the acetyl-CoA produced from glycolysis, shunting it to ketogenesis.
2. unrestrained lipolysis in adipose tissue due to the absence of insulin's inhibitory effect on hormone-sensitive lipase. (correct answer)
3. direct allosteric activation of ketogenic enzymes in the liver by pathologically high concentrations of blood glucose.
4. a profound decrease in the uptake of fatty acids by muscle tissue, causing them to accumulate in the liver for ketone synthesis.

Explanation: The correct answer is B. In Type 1 diabetes, the absolute lack of insulin removes the tonic inhibition of hormone-sensitive lipase in adipocytes. This leads to massive, uncontrolled breakdown of triacylglycerols (lipolysis), releasing a flood of free fatty acids into the bloodstream. These fatty acids are taken up by the liver, where their β-oxidation produces an overwhelming amount of acetyl-CoA that exceeds the capacity of the TCA cycle, forcing the excess into ketone body synthesis. A is a contributing factor but not the initiating event. The depletion of oxaloacetate (for gluconeogenesis) helps drive acetyl-CoA to ketogenesis, but this occurs after the massive influx of fatty acids, which is the primary trigger. C is incorrect; high glucose does not directly activate ketogenic enzymes. D is incorrect because fatty acid uptake by muscle is not the primary regulated step that fails; the massive release from adipose tissue is the key initiating pathology.

Question 10

1. An absolute deficiency of insulin has led to uncontrolled gluconeogenesis and ketogenesis, consistent with Type 1 diabetes. (correct answer)
2. Severe insulin resistance has impaired glucose uptake, but enough insulin is present to suppress ketosis, consistent with Type 2 diabetes.
3. The patient's symptoms are due to renal failure, where impaired glucose filtration and acid excretion mimic a diabetic state.
4. A defect in a gluconeogenic enzyme is causing a buildup of glucose precursors that are subsequently converted to ketones.

Explanation: The correct answer is A. The patient presents with the classic triad of diabetic ketoacidosis (DKA): hyperglycemia (550 mg/dL), acidosis (pH 7.15), and ketosis (high β-hydroxybutyrate). The key diagnostic clue is the undetectable C-peptide level. C-peptide is cleaved from proinsulin when insulin is produced. An undetectable level indicates the pancreatic β-cells are not producing insulin, which is the hallmark of Type 1 diabetes. B is incorrect because the presence of severe ketosis is inconsistent with the typical presentation of Type 2 diabetes, where some residual insulin is usually sufficient to suppress unrestrained ketogenesis. Also, the C-peptide would likely be normal or high in early T2D. C is incorrect because while renal function is affected in DKA, the underlying cause is metabolic, not renal failure. D is incorrect because a defect in a gluconeogenic enzyme would lead to hypoglycemia, not the severe hyperglycemia observed.

Question 11

1. Phenylalanine is an essential amino acid and is required as a building block for the synthesis of all cellular proteins. (correct answer)
2. A small amount of phenylalanine is necessary to allosterically activate the residual function of the defective hydroxylase enzyme.
3. Complete removal of phenylalanine would cause a toxic accumulation of its metabolic precursors, such as chorismate.
4. The body requires a low level of phenylalanine to maintain the production of phenylacetate for proper renal function.

Explanation: The correct answer is A. Phenylalanine is one of the essential amino acids, meaning humans cannot synthesize it and must obtain it from their diet. It is a necessary component for the synthesis of all proteins. Therefore, while intake must be restricted to prevent its accumulation to toxic levels in PKU patients, it cannot be completely eliminated without causing a different form of malnutrition and halting protein synthesis. B is incorrect; substrate concentration would not activate a genetically deficient enzyme in this manner. C is incorrect as chorismate is a precursor in the synthesis pathway of aromatic amino acids in plants and bacteria, not a precursor that would accumulate in humans. D is incorrect because phenylacetate is a toxic byproduct of excess phenylalanine and is not required for renal function.

Question 12

1. In Type 2 diabetes, circulating insulin, though insufficient for euglycemia, is adequate to suppress hormone-sensitive lipase. (correct answer)
2. Hepatocytes in Type 2 diabetics develop resistance to glucagon's ketogenic signals in parallel with their insulin resistance.
3. The extreme hyperglycemia in Type 2 diabetes allosterically inhibits the carnitine shuttle, preventing fatty acid oxidation.
4. Peripheral tissues in Type 2 diabetics have a greatly enhanced capacity for ketone body utilization compared to those in Type 1.

Explanation: The correct answer is A. The development of DKA requires near-total lack of insulin's effects. One of insulin's most sensitive actions is the suppression of hormone-sensitive lipase in adipose tissue. In Type 2 diabetes, there is insulin resistance, but patients still produce some endogenous insulin. This small amount is often sufficient to prevent the runaway lipolysis that provides the massive fatty acid substrate load for ketogenesis in the liver. Thus, while hyperglycemia can be severe, ketogenesis is held in check. B is incorrect; there is no evidence that glucagon resistance develops in this specific manner. C is incorrect; malonyl-CoA (from fatty acid synthesis) inhibits the carnitine shuttle, but fatty acid synthesis is low in the diabetic state, and glucose itself does not have this effect. D is incorrect; there is no significant difference in the capacity for ketone body utilization between the two types.

Question 13

1. stimulating the release of pre-synthesized insulin from storage vesicles in pancreatic β-cells.
2. inhibiting transcriptional expression of key gluconeogenic enzymes in the liver, thus reducing hepatic glucose output. (correct answer)
3. potentiating the signaling cascade of glucagon, leading to more efficient glycogenolysis in the fed state.
4. blocking the action of the GLUT4 transporter at the muscle cell surface, preventing glucose-induced toxicity.

Explanation: When you encounter questions about diabetes medications and their mechanisms, focus on understanding how different drugs target distinct pathways in glucose homeostasis. Metformin's mechanism centers on AMPK activation, which acts as a cellular energy sensor. AMPK activation by metformin primarily reduces hepatic glucose production through transcriptional regulation. When AMPK is activated, it phosphorylates and inactivates key transcription factors like CREB and ChREBP, which normally promote expression of gluconeogenic enzymes such as PEPCK and G6Pase. This transcriptional suppression means the liver produces less glucose, directly addressing the elevated blood glucose characteristic of Type 2 diabetes. Option A is incorrect because metformin doesn't target pancreatic β-cells or insulin release mechanisms - that's the mechanism of sulfonylureas like glyburide. Option C misrepresents both metformin's target and physiological logic, as glucagon promotes glucose production (the opposite of what's therapeutic), and efficient glycogenolysis in the fed state would be counterproductive. Option D contradicts metformin's actual effect - AMPK activation actually enhances GLUT4 translocation to increase glucose uptake, and blocking glucose transport would worsen hyperglycemia rather than treat it. The key study strategy for diabetes pharmacology is to categorize medications by their primary targets: β-cell insulin release (sulfonylureas), insulin sensitivity (thiazolidinediones), glucose absorption (α-glucosidase inhibitors), or hepatic glucose production (metformin). Understanding that metformin uniquely targets the liver's glucose output through AMPK will help you recognize its mechanism among distractors.

Question 14

1. a mutation in the insulin gene that produces a non-functional hormone incapable of binding its receptor.
2. a complete absence of functional insulin receptors on the plasma membranes of muscle and adipose cells.
3. the autoimmune destruction of pancreatic β-cells, leading to an inability to produce sufficient insulin.
4. a failure of intracellular signaling cascades downstream of a ligand-bound insulin receptor in target tissues. (correct answer)

Explanation: When analyzing insulin resistance in Type 2 diabetes, you need to distinguish between problems with insulin production, receptor binding, and intracellular signaling. The key insight is that insulin resistance occurs despite normal insulin levels and functional receptors. In early Type 2 diabetes, insulin resistance means that target tissues (muscle, liver, adipose) don't respond appropriately to insulin signals. The insulin molecule itself is normal and can bind to its receptor successfully. However, once the insulin-receptor complex forms, the downstream signaling cascade becomes impaired. This includes problems with insulin receptor substrate (IRS) proteins, PI3K/Akt pathway activation, and ultimately glucose transporter (GLUT4) translocation to the cell membrane. The result is reduced glucose uptake despite adequate insulin signaling at the receptor level. Option A describes a genetic defect producing non-functional insulin, which would be a form of diabetes but not insulin resistance. Option B suggests complete absence of insulin receptors, which would prevent any insulin response rather than creating resistance. Option C describes Type 1 diabetes, where autoimmune destruction of β-cells leads to insulin deficiency, not resistance. Option D correctly identifies that the problem lies in the intracellular signaling pathways that function downstream of the successfully bound insulin receptor. Study tip: Remember that "resistance" in biochemistry typically means the signaling machinery is present but not working efficiently. Look for answers that describe impaired signal transduction rather than absent components when you see resistance-related questions.

Question 15

1. α-Ketoisocaproate
2. Homogentisate
3. Phenylacetate (correct answer)
4. Tyramine

Explanation: When you encounter questions about metabolic disorders like PKU (phenylketonuria), focus on understanding how enzyme deficiencies create metabolic bottlenecks that redirect substrates into alternative pathways. In PKU, phenylalanine hydroxylase is deficient, preventing the normal conversion of phenylalanine to tyrosine. When phenylalanine accumulates to pathologically high levels, it overwhelms the primary metabolic pathway and gets shunted into normally minor alternative routes. One such pathway involves transamination of phenylalanine to phenylpyruvate, which is then metabolized through several steps including decarboxylation and reduction, ultimately producing phenylacetate. This compound, along with phenylpyruvate itself, gives PKU patients' urine its characteristic musty odor and serves as a diagnostic marker. Choice C (phenylacetate) is correct because it's directly derived from the alternative metabolism of accumulated phenylalanine in PKU patients. Choice A (α-ketoisocaproate) is wrong—this is a metabolite of leucine, not phenylalanine, and is associated with maple syrup urine disease. Choice B (homogentisate) is incorrect because it's an intermediate in tyrosine metabolism that accumulates in alkaptonuria, not PKU. Choice D (tyramine) is wrong since PKU actually results in decreased tyrosine production, not increased tyramine formation. Remember that in metabolic disorder questions, the key is tracing the metabolic consequences of specific enzyme deficiencies. When the normal pathway is blocked, substrates accumulate and flow into alternative routes, creating characteristic metabolic signatures that become diagnostic tools.

Question 16

1. HbA1c percentage
2. Fasting blood glucose concentration
3. Serum C-peptide levels (correct answer)
4. Presence of ketones in the urine

Explanation: When distinguishing between Type 1 and Type 2 diabetes in newly diagnosed patients, you need to focus on pancreatic beta cell function rather than just glucose control measures. C-peptide levels (C) provide the most definitive biochemical distinction because they directly reflect endogenous insulin production. C-peptide is released in equimolar amounts with insulin from pancreatic beta cells. In Type 1 diabetes, autoimmune destruction of beta cells leads to severely reduced or absent C-peptide levels, while Type 2 diabetes patients retain significant beta cell function early in the disease, producing normal or even elevated C-peptide levels due to insulin resistance. HbA1c (A) reflects average glucose control over 2-3 months but doesn't distinguish between diabetes types. Both Type 1 and Type 2 patients can present with similarly elevated HbA1c levels depending on how long hyperglycemia has been present. Fasting glucose (B) indicates the presence of diabetes but not the underlying pathophysiology. Both types can present with identical fasting glucose elevations, making this measurement diagnostically unhelpful for type differentiation. Urinary ketones (D) can be misleading because while more common in Type 1 diabetes, they can also occur in Type 2 patients during severe hyperglycemia, illness, or prolonged fasting. Ketones indicate inadequate insulin action but don't specifically indicate the cause. Study tip: Remember that C-peptide is your window into pancreatic function. Low C-peptide = inadequate insulin production (Type 1), while normal/high C-peptide = insulin resistance (Type 2). This distinction is crucial for appropriate treatment decisions.

Question 17

1. Enzymatic glycosylation of hemoglobin β-chains occurs proportionally to glucose concentration through hexokinase-mediated phosphorylation
2. Non-enzymatic glycation of hemoglobin amino groups occurs proportionally to glucose concentration and reflects long-term glycemic control (correct answer)
3. Oxidative modification of hemoglobin iron centers by glucose metabolites creates stable adducts measured as HbA1c
4. Competitive inhibition of hemoglobin oxygen binding by glucose creates conformational changes detected as glycated hemoglobin

Explanation: HbA1c formation involves non-enzymatic glycation (not glycosylation) of amino groups on hemoglobin, primarily the N-terminal valine of β-globin chains. This process is directly proportional to glucose concentration and time, making it an excellent marker of average glycemic control over the lifespan of red blood cells (120 days). Choice A incorrectly describes enzymatic phosphorylation. Choice C incorrectly focuses on iron oxidation rather than amino group modification. Choice D incorrectly suggests competitive inhibition affecting oxygen binding.

Question 18

1. Defective collagen cross-linking due to inadequate cysteine availability for disulfide bond formation in structural proteins
2. Impaired methylation reactions due to S-adenosylmethionine depletion from blocked homocysteine metabolism
3. Toxic accumulation of methionine metabolites leading to hepatic dysfunction and altered protein synthesis
4. Reduced glutathione synthesis due to cysteine deficiency, leading to oxidative stress and cellular damage (correct answer)

Explanation: Homocystinuria typically results from cystathionine β-synthase deficiency, blocking the conversion of homocysteine to cystathionine and subsequently to cysteine. Cysteine is essential for glutathione synthesis, and its deficiency leads to reduced antioxidant capacity and oxidative stress. This contributes to the vascular and connective tissue problems seen in homocystinuria. Choice A confuses cysteine's role in glutathione vs. structural proteins. Choice B is incorrect because SAM levels are typically elevated, not depleted. Choice C doesn't reflect the primary pathophysiology of cysteine deficiency.

Question 19

1. Activation of glycogen synthase through dephosphorylation while simultaneously inhibiting glycogen phosphorylase through phosphorylation (correct answer)
2. Stimulation of gluconeogenesis to rapidly increase glucose production from amino acid precursors in the liver
3. Enhanced fatty acid oxidation to provide alternative fuel sources while sparing glucose for neural tissue
4. Immediate activation of the pentose phosphate pathway to generate NADPH for biosynthetic reactions

Explanation: Glucose administration triggers insulin release, which activates protein phosphatase-1, leading to dephosphorylation and activation of glycogen synthase while simultaneously inactivating glycogen phosphorylase. This rapidly shifts from glycogen breakdown to glycogen synthesis. Choice B is incorrect because gluconeogenesis would be inhibited, not stimulated, by glucose/insulin. Choice C describes the fasting state response, opposite to glucose administration. Choice D, while the PPP is important, is not the immediate priority during hypoglycemia recovery.

Question 20

1. Phenylalanine hydroxylase deficiency, insulin receptor defects, glucose-6-phosphatase deficiency
2. Tyrosinase deficiency, pancreatic β-cell destruction, glycogen phosphorylase deficiency
3. Phenylalanine hydroxylase deficiency, pancreatic β-cell destruction, glucose-6-phosphatase deficiency (correct answer)
4. Branched-chain amino acid transaminase deficiency, insulin receptor defects, glycogen synthase deficiency

Explanation: Patient A shows classic PKU (phenylalanine hydroxylase deficiency). Patient B shows type 1 diabetes characteristics (β-cell destruction leading to insulin deficiency). Patient C shows fasting hypoglycemia with normal fed-state glucose, consistent with glucose-6-phosphatase deficiency (von Gierke disease) where glycogenolysis is impaired but glycogen synthesis works normally. Choice A incorrectly suggests insulin receptor defects for type 1 diabetes. Choice B misidentifies PKU as tyrosinase deficiency (albinism) and suggests glycogen phosphorylase deficiency (which would cause exercise intolerance, not fasting hypoglycemia). Choice D incorrectly identifies maple syrup urine disease instead of PKU.